We do have COVID-19 IgG/IgM Immunoassay rapid tests to fight the pandemic
We are a women's health solutions company accelerating access to innovations. The company is a leading expert in maternal and newborn health, with a focus on medical devices, diagnostics, pharmaceuticals and medical nutrition products that are appropriate for low and middle income countries.
We were incorporated in May 2009. We evolved to become a research marketplace in early 2011 in response to users and we initiated sales in 2012 with an introductory midwifery kit focused on postpartum hemorrhage. By 2015 we had started an ecommerce marketplace with more than 15 innovations. By 2020 we continued to expand into nutrition and child health and to carry more than 45 evidence-based innovations, many with the Maternova brand.
Our customers include private hospitals, non-profits, humanitarian organizations, governments and research institutions around the world. We have sold into 60 countries including the Madagascar, U.S., Canada, Mexico, Brazil, Colombia, Peru, Haiti, Germany, the UK, Pakistan, India, Kenya, Tanzania, Ethiopia, Uganda, Nigeria, South Africa, Bangladesh and Australia.
We sell to procurement agencies and procurement officials who equip frontline physicians, nurses, midwives and community health workers in low and middle income countries.
We started with maternal and newborn health because it has previously been overshadowed by other global health issues. As our model began to yield results for maternal/neonatal health, we folded in infectious diseases. Initial expansion has begun into nutrition and child health as well as other areas of Neglected Tropical Disease (NTD).
Maternova started with devices and technologies because there is so much going on in this area and no single trusted source for procuring, researching and reviewing medical technologies. We plan to expand into training for techniques, procedures and protocols.
Maternova is a C-corporation. We also have a platinum rating for social impact from a B-lab rating review. Maternova is a social enterprise, a mission-driven company structured to operate in the global health commercial markets but driven by an unyielding social and public health mission--to save more maternal and newborn lives more quickly.
Maternova licenses medical devices and diagnostics or develops exclusive distribution agreements with innovators. We then use our unique channels to accelerate market entry in emerging markets and sell to governments, hospitals and humanitarian organizations around the world. We understand the markets for medical products in low- and middle-income countries and keep our margins low and our shipping and logistics streamlined and low-cost.
There are many terrific organizations that have done advocacy and research to bring maternal and newborn health issues to the fore around the globe. There are also dozens of scientists and innovators developing new technologies for global health. But there is only one trusted online marketplace curating, evaluating and selling these devices and diagnostics. Maternova has domain expertise in public health, epidemiology, biotech, obstetrics and neonatology. Coupled with our understanding of the unique needs of clinics, hospitals, governments and humanitarian organizations, we are the only company sourcing, vetting, selling and providing end to end logistics for medical products being used in the most remote settings around the world.
Our signature innovation is the NASG, non pneumatic anti shock garment to stop postpartum hemorrhage and reduce maternal mortality. We have worked with midwives and physicians from around the world, from Cameroon to Haiti. While we started with a focus on obstetrics and hemorrhage, we have a deep understanding of the underlying causes of poor health outcomes, including micronutrient deficiencies, acute malnutrition, anemia, neglected tropical disease infections, infectious diseases and poverty.
© 2022 Maternova is a trusted source for obstetric, newborn and reproductive health innovations. We focus on eclampsia and hemorrhage as well as newborn resuscitation.
